【抗癌“创新药舰队”高歌猛进 助阿斯利康(AZN.US)业绩超预期】智通财经APP获悉,全球创新药领域可谓迎来重大业绩增长层面的利好,总部位于英国的医药巨头阿斯利康公司(AZN.US)第二季度总营收优于华尔街分析师预期,并且利润增速强劲,主要得益于其聚焦于抗癌的创新药物组合所带来的强劲创收能力以及美国市场需求扩张。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.